Although CXCL5 inhibitors have not yet been tested in cancer patients, their blockade of neutrophil recruitment and anti-angiogenesis actions provide a direction for the future treatment of pancreatic cancer patients. This evidence concerns the gene CXCL5 and pancreatic neoplasm.